In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...

Vaccine stocks slipped in late afternoon trade on Thursday after multiple reports indicated President-elect Donald Trump would name anti-vaccine activist Robert F. Kennedy Jr. to lead the Department ...